Global Anti-IL-23 p19 Monoclonal Antibodies Market Growth 2026-2032
The global Anti-IL-23 p19 Monoclonal Antibodies market size is predicted to grow from US$ 23576 million in 2025 to US$ 46859 million in 2032; it is expected to grow at a CAGR of 8.8% from 2026 to 2032.
Anti-IL-23 p19 monoclonal antibodies are recombinant therapeutic biologics designed to selectively bind the p19 subunit of interleukin 23 and treat immune-mediated inflammatory diseases. The product scope mainly covers humanized or fully human IgG monoclonal antibody injections, including prefilled syringes, autoinjectors, subcutaneous formulations and intravenous induction formulations used in selected indications. Core manufacturing processes include antibody discovery and optimization, mammalian cell expression, cell culture, protein A purification, viral inactivation, ultrafiltration and concentration, aseptic filling, cold-chain release testing and biologics quality control. Key specifications include target-binding affinity, p19 selectivity, serum half-life, dosing interval, immunogenicity, formulation stability, purity, aggregate level, potency and batch-to-batch consistency. The main therapeutic function is to inhibit IL-23-mediated activation of the Th17 inflammatory pathway and reduce downstream cytokine activity, thereby improving chronic inflammatory diseases such as moderate to severe plaque psoriasis, psoriatic arthritis, Crohn?s disease and ulcerative colitis. The industry is positioned within specialty biologics and autoimmune therapeutics, with demand driven by long-term treatment, expanded indications, improved dosing convenience and substitution from older immunology therapies. In 2025, mature commercialized anti-IL-23 p19 monoclonal antibody products generally achieved gross margins of about 80% to 90%.
Anti-IL-23 p19 monoclonal antibodies represent one of the most commercially established segments within specialty immunology biologics. The market is not characterized by a large number of manufacturers, but by a small group of approved therapies that have built strong positions through clear target selectivity, durable efficacy, convenient dosing and continuous indication expansion. The upstream chain includes cell line development, culture media, single-use bioreactors, purification resins, sterile filling materials and cold-chain systems. The midstream consists of antibody discovery, clinical development, regulatory registration, large-scale biologics manufacturing and quality release. The downstream market is concentrated in dermatology, rheumatology and gastroenterology, where chronic disease management and long treatment duration support resilient demand. Competition is highly concentrated, but the basis of competition is changing. Initial adoption was largely driven by plaque psoriasis, while future growth is increasingly linked to inflammatory bowel disease, psoriatic arthritis and broader immune-mediated conditions. New product launches and indication expansion remain the main commercial catalysts, but differentiation must be supported by sustained efficacy, safety, dosing convenience and real-world outcomes. Licensing, co-development and regional commercialization agreements are expected to remain active, particularly around late-stage pipelines and next-generation antibody formats. These transactions can improve development efficiency and accelerate geographic expansion, but they also make revenue attribution and market sizing more complex. The policy environment is broadly supportive of innovative biologics, especially where therapies address chronic inflammatory diseases with high unmet needs. At the same time, payer pressure, health technology assessment, price negotiation, biosimilar risk and patent-cycle dynamics will gradually moderate long-term growth. The industry remains a growth market, but it is moving from a rapid expansion phase toward a more mature phase driven by product differentiation and lifecycle management. Products with longer half-life, fewer injections, broader indication coverage and reliable manufacturing quality are likely to gain share, while late entrants with limited clinical or pricing advantages may face increasing commercialization pressure.
LP Information, Inc. (LPI) ' newest research report, the ?Anti-IL-23 p19 Monoclonal Antibodies Industry Forecast? looks at past sales and reviews total world Anti-IL-23 p19 Monoclonal Antibodies sales in 2025, providing a comprehensive analysis by region and market sector of projected Anti-IL-23 p19 Monoclonal Antibodies sales for 2026 through 2032. With Anti-IL-23 p19 Monoclonal Antibodies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-IL-23 p19 Monoclonal Antibodies industry.
This Insight Report provides a comprehensive analysis of the global Anti-IL-23 p19 Monoclonal Antibodies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-IL-23 p19 Monoclonal Antibodies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Anti-IL-23 p19 Monoclonal Antibodies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-IL-23 p19 Monoclonal Antibodies and breaks down the forecast by Indication, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-IL-23 p19 Monoclonal Antibodies.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-IL-23 p19 Monoclonal Antibodies market by product type, application, key manufacturers and key regions and countries.
Segmentation by Indication:
What is the 10-year outlook for the global Anti-IL-23 p19 Monoclonal Antibodies market?
What factors are driving Anti-IL-23 p19 Monoclonal Antibodies market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-IL-23 p19 Monoclonal Antibodies market opportunities vary by end market size?
How does Anti-IL-23 p19 Monoclonal Antibodies break out by Indication, by Application?
Anti-IL-23 p19 monoclonal antibodies are recombinant therapeutic biologics designed to selectively bind the p19 subunit of interleukin 23 and treat immune-mediated inflammatory diseases. The product scope mainly covers humanized or fully human IgG monoclonal antibody injections, including prefilled syringes, autoinjectors, subcutaneous formulations and intravenous induction formulations used in selected indications. Core manufacturing processes include antibody discovery and optimization, mammalian cell expression, cell culture, protein A purification, viral inactivation, ultrafiltration and concentration, aseptic filling, cold-chain release testing and biologics quality control. Key specifications include target-binding affinity, p19 selectivity, serum half-life, dosing interval, immunogenicity, formulation stability, purity, aggregate level, potency and batch-to-batch consistency. The main therapeutic function is to inhibit IL-23-mediated activation of the Th17 inflammatory pathway and reduce downstream cytokine activity, thereby improving chronic inflammatory diseases such as moderate to severe plaque psoriasis, psoriatic arthritis, Crohn?s disease and ulcerative colitis. The industry is positioned within specialty biologics and autoimmune therapeutics, with demand driven by long-term treatment, expanded indications, improved dosing convenience and substitution from older immunology therapies. In 2025, mature commercialized anti-IL-23 p19 monoclonal antibody products generally achieved gross margins of about 80% to 90%.
Anti-IL-23 p19 monoclonal antibodies represent one of the most commercially established segments within specialty immunology biologics. The market is not characterized by a large number of manufacturers, but by a small group of approved therapies that have built strong positions through clear target selectivity, durable efficacy, convenient dosing and continuous indication expansion. The upstream chain includes cell line development, culture media, single-use bioreactors, purification resins, sterile filling materials and cold-chain systems. The midstream consists of antibody discovery, clinical development, regulatory registration, large-scale biologics manufacturing and quality release. The downstream market is concentrated in dermatology, rheumatology and gastroenterology, where chronic disease management and long treatment duration support resilient demand. Competition is highly concentrated, but the basis of competition is changing. Initial adoption was largely driven by plaque psoriasis, while future growth is increasingly linked to inflammatory bowel disease, psoriatic arthritis and broader immune-mediated conditions. New product launches and indication expansion remain the main commercial catalysts, but differentiation must be supported by sustained efficacy, safety, dosing convenience and real-world outcomes. Licensing, co-development and regional commercialization agreements are expected to remain active, particularly around late-stage pipelines and next-generation antibody formats. These transactions can improve development efficiency and accelerate geographic expansion, but they also make revenue attribution and market sizing more complex. The policy environment is broadly supportive of innovative biologics, especially where therapies address chronic inflammatory diseases with high unmet needs. At the same time, payer pressure, health technology assessment, price negotiation, biosimilar risk and patent-cycle dynamics will gradually moderate long-term growth. The industry remains a growth market, but it is moving from a rapid expansion phase toward a more mature phase driven by product differentiation and lifecycle management. Products with longer half-life, fewer injections, broader indication coverage and reliable manufacturing quality are likely to gain share, while late entrants with limited clinical or pricing advantages may face increasing commercialization pressure.
LP Information, Inc. (LPI) ' newest research report, the ?Anti-IL-23 p19 Monoclonal Antibodies Industry Forecast? looks at past sales and reviews total world Anti-IL-23 p19 Monoclonal Antibodies sales in 2025, providing a comprehensive analysis by region and market sector of projected Anti-IL-23 p19 Monoclonal Antibodies sales for 2026 through 2032. With Anti-IL-23 p19 Monoclonal Antibodies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-IL-23 p19 Monoclonal Antibodies industry.
This Insight Report provides a comprehensive analysis of the global Anti-IL-23 p19 Monoclonal Antibodies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-IL-23 p19 Monoclonal Antibodies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Anti-IL-23 p19 Monoclonal Antibodies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-IL-23 p19 Monoclonal Antibodies and breaks down the forecast by Indication, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-IL-23 p19 Monoclonal Antibodies.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-IL-23 p19 Monoclonal Antibodies market by product type, application, key manufacturers and key regions and countries.
Segmentation by Indication:
- Plaque Psoriasis
- Psoriatic Arthritis
- Crohn's Disease
- Ulcerative Colitis
- Others
- Humanized IgG Monoclonal Antibodies
- Fully Human IgG Monoclonal Antibodies
- Fc-engineered or Long-acting Antibodies
- Others
- Subcutaneous Injection
- Intravenous Induction plus Subcutaneous Maintenance
- Intravenous Injection
- Others
- Hospitals
- Specialist Clinics
- Infusion Centers
- Specialty Pharmacies
- Retail and DTP Pharmacies
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AbbVie Inc.
- Johnson & Johnson
- Eli Lilly and Company
- Sun Pharmaceutical Industries Limited
- Innovent Biologics, Inc.
- Hansoh Pharmaceutical Group Company Limited
- SUN Pharmaceuticals Industries Europe B.V.
- Industrias Farmac?uticas Almirall, S.A.
What is the 10-year outlook for the global Anti-IL-23 p19 Monoclonal Antibodies market?
What factors are driving Anti-IL-23 p19 Monoclonal Antibodies market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Anti-IL-23 p19 Monoclonal Antibodies market opportunities vary by end market size?
How does Anti-IL-23 p19 Monoclonal Antibodies break out by Indication, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-IL-23 p19 Monoclonal Antibodies Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Anti-IL-23 p19 Monoclonal Antibodies by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Anti-IL-23 p19 Monoclonal Antibodies by Country/Region, 2021, 2025 & 2032
2.2 Anti-IL-23 p19 Monoclonal Antibodies Segment by Indication
2.2.1 Plaque Psoriasis
2.2.2 Psoriatic Arthritis
2.2.3 Crohn's Disease
2.2.4 Ulcerative Colitis
2.2.5 Others
2.2.6 Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication
2.2.6.1 Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Indication (2021-2026)
2.2.6.2 Global Anti-IL-23 p19 Monoclonal Antibodies Revenue and Market Share by Indication (2021-2026)
2.2.6.3 Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Indication (2021-2026)
2.3 Anti-IL-23 p19 Monoclonal Antibodies Segment by Molecule Type
2.3.1 Humanized IgG Monoclonal Antibodies
2.3.2 Fully Human IgG Monoclonal Antibodies
2.3.3 Fc-engineered or Long-acting Antibodies
2.3.4 Others
2.3.5 Anti-IL-23 p19 Monoclonal Antibodies Sales by Molecule Type
2.3.5.1 Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Molecule Type (2021-2026)
2.3.5.2 Global Anti-IL-23 p19 Monoclonal Antibodies Revenue and Market Share by Molecule Type (2021-2026)
2.3.5.3 Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Molecule Type (2021-2026)
2.4 Anti-IL-23 p19 Monoclonal Antibodies Segment by Route of Administration
2.4.1 Subcutaneous Injection
2.4.2 Intravenous Induction plus Subcutaneous Maintenance
2.4.3 Intravenous Injection
2.4.4 Others
2.4.5 Anti-IL-23 p19 Monoclonal Antibodies Sales by Route of Administration
2.4.5.1 Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Route of Administration (2021-2026)
2.4.5.2 Global Anti-IL-23 p19 Monoclonal Antibodies Revenue and Market Share by Route of Administration (2021-2026)
2.4.5.3 Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Route of Administration (2021-2026)
2.5 Anti-IL-23 p19 Monoclonal Antibodies Segment by Application
2.5.1 Hospitals
2.5.2 Specialist Clinics
2.5.3 Infusion Centers
2.5.4 Specialty Pharmacies
2.5.5 Retail and DTP Pharmacies
2.5.6 Others
2.5.7 Anti-IL-23 p19 Monoclonal Antibodies Sales by Application
2.5.7.1 Global Anti-IL-23 p19 Monoclonal Antibodies Sale Market Share by Application (2021-2026)
2.5.7.2 Global Anti-IL-23 p19 Monoclonal Antibodies Revenue and Market Share by Application (2021-2026)
2.5.7.3 Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Anti-IL-23 p19 Monoclonal Antibodies Breakdown Data by Company
3.1.1 Global Anti-IL-23 p19 Monoclonal Antibodies Annual Sales by Company (2021-2026)
3.1.2 Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Company (2021-2026)
3.2 Global Anti-IL-23 p19 Monoclonal Antibodies Annual Revenue by Company (2021-2026)
3.2.1 Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Company (2021-2026)
3.2.2 Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Company (2021-2026)
3.3 Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Company
3.4 Key Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Product Location Distribution
3.4.2 Players Anti-IL-23 p19 Monoclonal Antibodies Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTI-IL-23 P19 MONOCLONAL ANTIBODIES BY GEOGRAPHIC REGION
4.1 World Historic Anti-IL-23 p19 Monoclonal Antibodies Market Size by Geographic Region (2021-2026)
4.1.1 Global Anti-IL-23 p19 Monoclonal Antibodies Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Anti-IL-23 p19 Monoclonal Antibodies Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Anti-IL-23 p19 Monoclonal Antibodies Market Size by Country/Region (2021-2026)
4.2.1 Global Anti-IL-23 p19 Monoclonal Antibodies Annual Sales by Country/Region (2021-2026)
4.2.2 Global Anti-IL-23 p19 Monoclonal Antibodies Annual Revenue by Country/Region (2021-2026)
4.3 Americas Anti-IL-23 p19 Monoclonal Antibodies Sales Growth
4.4 APAC Anti-IL-23 p19 Monoclonal Antibodies Sales Growth
4.5 Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Growth
4.6 Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Growth
5 AMERICAS
5.1 Americas Anti-IL-23 p19 Monoclonal Antibodies Sales by Country
5.1.1 Americas Anti-IL-23 p19 Monoclonal Antibodies Sales by Country (2021-2026)
5.1.2 Americas Anti-IL-23 p19 Monoclonal Antibodies Revenue by Country (2021-2026)
5.2 Americas Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication (2021-2026)
5.3 Americas Anti-IL-23 p19 Monoclonal Antibodies Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-IL-23 p19 Monoclonal Antibodies Sales by Region
6.1.1 APAC Anti-IL-23 p19 Monoclonal Antibodies Sales by Region (2021-2026)
6.1.2 APAC Anti-IL-23 p19 Monoclonal Antibodies Revenue by Region (2021-2026)
6.2 APAC Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication (2021-2026)
6.3 APAC Anti-IL-23 p19 Monoclonal Antibodies Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Anti-IL-23 p19 Monoclonal Antibodies by Country
7.1.1 Europe Anti-IL-23 p19 Monoclonal Antibodies Sales by Country (2021-2026)
7.1.2 Europe Anti-IL-23 p19 Monoclonal Antibodies Revenue by Country (2021-2026)
7.2 Europe Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication (2021-2026)
7.3 Europe Anti-IL-23 p19 Monoclonal Antibodies Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies by Country
8.1.1 Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales by Country (2021-2026)
8.1.2 Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Revenue by Country (2021-2026)
8.2 Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication (2021-2026)
8.3 Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-IL-23 p19 Monoclonal Antibodies
10.3 Manufacturing Process Analysis of Anti-IL-23 p19 Monoclonal Antibodies
10.4 Industry Chain Structure of Anti-IL-23 p19 Monoclonal Antibodies
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-IL-23 p19 Monoclonal Antibodies Distributors
11.3 Anti-IL-23 p19 Monoclonal Antibodies Customer
12 WORLD FORECAST REVIEW FOR ANTI-IL-23 P19 MONOCLONAL ANTIBODIES BY GEOGRAPHIC REGION
12.1 Global Anti-IL-23 p19 Monoclonal Antibodies Market Size Forecast by Region
12.1.1 Global Anti-IL-23 p19 Monoclonal Antibodies Forecast by Region (2027-2032)
12.1.2 Global Anti-IL-23 p19 Monoclonal Antibodies Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Anti-IL-23 p19 Monoclonal Antibodies Forecast by Indication (2027-2032)
12.7 Global Anti-IL-23 p19 Monoclonal Antibodies Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 AbbVie Inc.
13.1.1 AbbVie Inc. Company Information
13.1.2 AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
13.1.3 AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 AbbVie Inc. Main Business Overview
13.1.5 AbbVie Inc. Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
13.2.3 Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Eli Lilly and Company
13.3.1 Eli Lilly and Company Company Information
13.3.2 Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
13.3.3 Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Eli Lilly and Company Main Business Overview
13.3.5 Eli Lilly and Company Latest Developments
13.4 Sun Pharmaceutical Industries Limited
13.4.1 Sun Pharmaceutical Industries Limited Company Information
13.4.2 Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
13.4.3 Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Sun Pharmaceutical Industries Limited Main Business Overview
13.4.5 Sun Pharmaceutical Industries Limited Latest Developments
13.5 Innovent Biologics, Inc.
13.5.1 Innovent Biologics, Inc. Company Information
13.5.2 Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
13.5.3 Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Innovent Biologics, Inc. Main Business Overview
13.5.5 Innovent Biologics, Inc. Latest Developments
13.6 Hansoh Pharmaceutical Group Company Limited
13.6.1 Hansoh Pharmaceutical Group Company Limited Company Information
13.6.2 Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
13.6.3 Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Hansoh Pharmaceutical Group Company Limited Main Business Overview
13.6.5 Hansoh Pharmaceutical Group Company Limited Latest Developments
13.7 SUN Pharmaceuticals Industries Europe B.V.
13.7.1 SUN Pharmaceuticals Industries Europe B.V. Company Information
13.7.2 SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
13.7.3 SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 SUN Pharmaceuticals Industries Europe B.V. Main Business Overview
13.7.5 SUN Pharmaceuticals Industries Europe B.V. Latest Developments
13.8 Industrias Farmac?uticas Almirall, S.A.
13.8.1 Industrias Farmac?uticas Almirall, S.A. Company Information
13.8.2 Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
13.8.3 Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Industrias Farmac?uticas Almirall, S.A. Main Business Overview
13.8.5 Industrias Farmac?uticas Almirall, S.A. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-IL-23 p19 Monoclonal Antibodies Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Anti-IL-23 p19 Monoclonal Antibodies by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Anti-IL-23 p19 Monoclonal Antibodies by Country/Region, 2021, 2025 & 2032
2.2 Anti-IL-23 p19 Monoclonal Antibodies Segment by Indication
2.2.1 Plaque Psoriasis
2.2.2 Psoriatic Arthritis
2.2.3 Crohn's Disease
2.2.4 Ulcerative Colitis
2.2.5 Others
2.2.6 Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication
2.2.6.1 Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Indication (2021-2026)
2.2.6.2 Global Anti-IL-23 p19 Monoclonal Antibodies Revenue and Market Share by Indication (2021-2026)
2.2.6.3 Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Indication (2021-2026)
2.3 Anti-IL-23 p19 Monoclonal Antibodies Segment by Molecule Type
2.3.1 Humanized IgG Monoclonal Antibodies
2.3.2 Fully Human IgG Monoclonal Antibodies
2.3.3 Fc-engineered or Long-acting Antibodies
2.3.4 Others
2.3.5 Anti-IL-23 p19 Monoclonal Antibodies Sales by Molecule Type
2.3.5.1 Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Molecule Type (2021-2026)
2.3.5.2 Global Anti-IL-23 p19 Monoclonal Antibodies Revenue and Market Share by Molecule Type (2021-2026)
2.3.5.3 Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Molecule Type (2021-2026)
2.4 Anti-IL-23 p19 Monoclonal Antibodies Segment by Route of Administration
2.4.1 Subcutaneous Injection
2.4.2 Intravenous Induction plus Subcutaneous Maintenance
2.4.3 Intravenous Injection
2.4.4 Others
2.4.5 Anti-IL-23 p19 Monoclonal Antibodies Sales by Route of Administration
2.4.5.1 Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Route of Administration (2021-2026)
2.4.5.2 Global Anti-IL-23 p19 Monoclonal Antibodies Revenue and Market Share by Route of Administration (2021-2026)
2.4.5.3 Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Route of Administration (2021-2026)
2.5 Anti-IL-23 p19 Monoclonal Antibodies Segment by Application
2.5.1 Hospitals
2.5.2 Specialist Clinics
2.5.3 Infusion Centers
2.5.4 Specialty Pharmacies
2.5.5 Retail and DTP Pharmacies
2.5.6 Others
2.5.7 Anti-IL-23 p19 Monoclonal Antibodies Sales by Application
2.5.7.1 Global Anti-IL-23 p19 Monoclonal Antibodies Sale Market Share by Application (2021-2026)
2.5.7.2 Global Anti-IL-23 p19 Monoclonal Antibodies Revenue and Market Share by Application (2021-2026)
2.5.7.3 Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Anti-IL-23 p19 Monoclonal Antibodies Breakdown Data by Company
3.1.1 Global Anti-IL-23 p19 Monoclonal Antibodies Annual Sales by Company (2021-2026)
3.1.2 Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Company (2021-2026)
3.2 Global Anti-IL-23 p19 Monoclonal Antibodies Annual Revenue by Company (2021-2026)
3.2.1 Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Company (2021-2026)
3.2.2 Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Company (2021-2026)
3.3 Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Company
3.4 Key Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Product Location Distribution
3.4.2 Players Anti-IL-23 p19 Monoclonal Antibodies Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTI-IL-23 P19 MONOCLONAL ANTIBODIES BY GEOGRAPHIC REGION
4.1 World Historic Anti-IL-23 p19 Monoclonal Antibodies Market Size by Geographic Region (2021-2026)
4.1.1 Global Anti-IL-23 p19 Monoclonal Antibodies Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Anti-IL-23 p19 Monoclonal Antibodies Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Anti-IL-23 p19 Monoclonal Antibodies Market Size by Country/Region (2021-2026)
4.2.1 Global Anti-IL-23 p19 Monoclonal Antibodies Annual Sales by Country/Region (2021-2026)
4.2.2 Global Anti-IL-23 p19 Monoclonal Antibodies Annual Revenue by Country/Region (2021-2026)
4.3 Americas Anti-IL-23 p19 Monoclonal Antibodies Sales Growth
4.4 APAC Anti-IL-23 p19 Monoclonal Antibodies Sales Growth
4.5 Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Growth
4.6 Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Growth
5 AMERICAS
5.1 Americas Anti-IL-23 p19 Monoclonal Antibodies Sales by Country
5.1.1 Americas Anti-IL-23 p19 Monoclonal Antibodies Sales by Country (2021-2026)
5.1.2 Americas Anti-IL-23 p19 Monoclonal Antibodies Revenue by Country (2021-2026)
5.2 Americas Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication (2021-2026)
5.3 Americas Anti-IL-23 p19 Monoclonal Antibodies Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-IL-23 p19 Monoclonal Antibodies Sales by Region
6.1.1 APAC Anti-IL-23 p19 Monoclonal Antibodies Sales by Region (2021-2026)
6.1.2 APAC Anti-IL-23 p19 Monoclonal Antibodies Revenue by Region (2021-2026)
6.2 APAC Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication (2021-2026)
6.3 APAC Anti-IL-23 p19 Monoclonal Antibodies Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Anti-IL-23 p19 Monoclonal Antibodies by Country
7.1.1 Europe Anti-IL-23 p19 Monoclonal Antibodies Sales by Country (2021-2026)
7.1.2 Europe Anti-IL-23 p19 Monoclonal Antibodies Revenue by Country (2021-2026)
7.2 Europe Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication (2021-2026)
7.3 Europe Anti-IL-23 p19 Monoclonal Antibodies Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies by Country
8.1.1 Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales by Country (2021-2026)
8.1.2 Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Revenue by Country (2021-2026)
8.2 Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication (2021-2026)
8.3 Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-IL-23 p19 Monoclonal Antibodies
10.3 Manufacturing Process Analysis of Anti-IL-23 p19 Monoclonal Antibodies
10.4 Industry Chain Structure of Anti-IL-23 p19 Monoclonal Antibodies
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-IL-23 p19 Monoclonal Antibodies Distributors
11.3 Anti-IL-23 p19 Monoclonal Antibodies Customer
12 WORLD FORECAST REVIEW FOR ANTI-IL-23 P19 MONOCLONAL ANTIBODIES BY GEOGRAPHIC REGION
12.1 Global Anti-IL-23 p19 Monoclonal Antibodies Market Size Forecast by Region
12.1.1 Global Anti-IL-23 p19 Monoclonal Antibodies Forecast by Region (2027-2032)
12.1.2 Global Anti-IL-23 p19 Monoclonal Antibodies Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Anti-IL-23 p19 Monoclonal Antibodies Forecast by Indication (2027-2032)
12.7 Global Anti-IL-23 p19 Monoclonal Antibodies Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 AbbVie Inc.
13.1.1 AbbVie Inc. Company Information
13.1.2 AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
13.1.3 AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 AbbVie Inc. Main Business Overview
13.1.5 AbbVie Inc. Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
13.2.3 Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Eli Lilly and Company
13.3.1 Eli Lilly and Company Company Information
13.3.2 Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
13.3.3 Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Eli Lilly and Company Main Business Overview
13.3.5 Eli Lilly and Company Latest Developments
13.4 Sun Pharmaceutical Industries Limited
13.4.1 Sun Pharmaceutical Industries Limited Company Information
13.4.2 Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
13.4.3 Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Sun Pharmaceutical Industries Limited Main Business Overview
13.4.5 Sun Pharmaceutical Industries Limited Latest Developments
13.5 Innovent Biologics, Inc.
13.5.1 Innovent Biologics, Inc. Company Information
13.5.2 Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
13.5.3 Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Innovent Biologics, Inc. Main Business Overview
13.5.5 Innovent Biologics, Inc. Latest Developments
13.6 Hansoh Pharmaceutical Group Company Limited
13.6.1 Hansoh Pharmaceutical Group Company Limited Company Information
13.6.2 Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
13.6.3 Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Hansoh Pharmaceutical Group Company Limited Main Business Overview
13.6.5 Hansoh Pharmaceutical Group Company Limited Latest Developments
13.7 SUN Pharmaceuticals Industries Europe B.V.
13.7.1 SUN Pharmaceuticals Industries Europe B.V. Company Information
13.7.2 SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
13.7.3 SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 SUN Pharmaceuticals Industries Europe B.V. Main Business Overview
13.7.5 SUN Pharmaceuticals Industries Europe B.V. Latest Developments
13.8 Industrias Farmac?uticas Almirall, S.A.
13.8.1 Industrias Farmac?uticas Almirall, S.A. Company Information
13.8.2 Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
13.8.3 Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Industrias Farmac?uticas Almirall, S.A. Main Business Overview
13.8.5 Industrias Farmac?uticas Almirall, S.A. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Anti-IL-23 p19 Monoclonal Antibodies Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Anti-IL-23 p19 Monoclonal Antibodies Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Plaque Psoriasis
Table 4. Major Players of Psoriatic Arthritis
Table 5. Major Players of Crohn's Disease
Table 6. Major Players of Ulcerative Colitis
Table 7. Major Players of Others
Table 8. Global Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication (2021-2026) & (Unit)
Table 9. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Indication (2021-2026)
Table 10. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Indication (2021-2026) & ($ million)
Table 11. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Indication (2021-2026)
Table 12. Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Indication (2021-2026) & (US$/Unit)
Table 13. Major Players of Humanized IgG Monoclonal Antibodies
Table 14. Major Players of Fully Human IgG Monoclonal Antibodies
Table 15. Major Players of Fc-engineered or Long-acting Antibodies
Table 16. Major Players of Others
Table 17. Global Anti-IL-23 p19 Monoclonal Antibodies Sales by Molecule Type (2021-2026) & (Unit)
Table 18. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Molecule Type (2021-2026)
Table 19. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Molecule Type (2021-2026) & ($ million)
Table 20. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Molecule Type (2021-2026)
Table 21. Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Molecule Type (2021-2026) & (US$/Unit)
Table 22. Major Players of Subcutaneous Injection
Table 23. Major Players of Intravenous Induction plus Subcutaneous Maintenance
Table 24. Major Players of Intravenous Injection
Table 25. Major Players of Others
Table 26. Global Anti-IL-23 p19 Monoclonal Antibodies Sales by Route of Administration (2021-2026) & (Unit)
Table 27. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Route of Administration (2021-2026)
Table 28. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Route of Administration (2021-2026) & ($ million)
Table 29. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Route of Administration (2021-2026)
Table 30. Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Route of Administration (2021-2026) & (US$/Unit)
Table 31. Global Anti-IL-23 p19 Monoclonal Antibodies Sale by Application (2021-2026) & (Unit)
Table 32. Global Anti-IL-23 p19 Monoclonal Antibodies Sale Market Share by Application (2021-2026)
Table 33. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Application (2021-2026) & ($ million)
Table 34. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Application (2021-2026)
Table 35. Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Application (2021-2026) & (US$/Unit)
Table 36. Global Anti-IL-23 p19 Monoclonal Antibodies Sales by Company (2021-2026) & (Unit)
Table 37. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Company (2021-2026)
Table 38. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Company (2021-2026) & ($ millions)
Table 39. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Company (2021-2026)
Table 40. Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Company (2021-2026) & (US$/Unit)
Table 41. Key Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Producing Area Distribution and Sales Area
Table 42. Players Anti-IL-23 p19 Monoclonal Antibodies Products Offered
Table 43. Anti-IL-23 p19 Monoclonal Antibodies Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 44. New Products and Potential Entrants
Table 45. Market M&A Activity & Strategy
Table 46. Global Anti-IL-23 p19 Monoclonal Antibodies Sales by Geographic Region (2021-2026) & (Unit)
Table 47. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share Geographic Region (2021-2026)
Table 48. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Geographic Region (2021-2026) & ($ millions)
Table 49. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Geographic Region (2021-2026)
Table 50. Global Anti-IL-23 p19 Monoclonal Antibodies Sales by Country/Region (2021-2026) & (Unit)
Table 51. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Country/Region (2021-2026)
Table 52. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Country/Region (2021-2026) & ($ millions)
Table 53. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Country/Region (2021-2026)
Table 54. Americas Anti-IL-23 p19 Monoclonal Antibodies Sales by Country (2021-2026) & (Unit)
Table 55. Americas Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Country (2021-2026)
Table 56. Americas Anti-IL-23 p19 Monoclonal Antibodies Revenue by Country (2021-2026) & ($ millions)
Table 57. Americas Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication (2021-2026) & (Unit)
Table 58. Americas Anti-IL-23 p19 Monoclonal Antibodies Sales by Application (2021-2026) & (Unit)
Table 59. APAC Anti-IL-23 p19 Monoclonal Antibodies Sales by Region (2021-2026) & (Unit)
Table 60. APAC Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Region (2021-2026)
Table 61. APAC Anti-IL-23 p19 Monoclonal Antibodies Revenue by Region (2021-2026) & ($ millions)
Table 62. APAC Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication (2021-2026) & (Unit)
Table 63. APAC Anti-IL-23 p19 Monoclonal Antibodies Sales by Application (2021-2026) & (Unit)
Table 64. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales by Country (2021-2026) & (Unit)
Table 65. Europe Anti-IL-23 p19 Monoclonal Antibodies Revenue by Country (2021-2026) & ($ millions)
Table 66. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication (2021-2026) & (Unit)
Table 67. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales by Application (2021-2026) & (Unit)
Table 68. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales by Country (2021-2026) & (Unit)
Table 69. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Country (2021-2026)
Table 70. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication (2021-2026) & (Unit)
Table 71. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales by Application (2021-2026) & (Unit)
Table 72. Key Market Drivers & Growth Opportunities of Anti-IL-23 p19 Monoclonal Antibodies
Table 73. Key Market Challenges & Risks of Anti-IL-23 p19 Monoclonal Antibodies
Table 74. Key Industry Trends of Anti-IL-23 p19 Monoclonal Antibodies
Table 75. Anti-IL-23 p19 Monoclonal Antibodies Raw Material
Table 76. Key Suppliers of Raw Materials
Table 77. Anti-IL-23 p19 Monoclonal Antibodies Distributors List
Table 78. Anti-IL-23 p19 Monoclonal Antibodies Customer List
Table 79. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Forecast by Region (2027-2032) & (Unit)
Table 80. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Americas Anti-IL-23 p19 Monoclonal Antibodies Sales Forecast by Country (2027-2032) & (Unit)
Table 82. Americas Anti-IL-23 p19 Monoclonal Antibodies Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. APAC Anti-IL-23 p19 Monoclonal Antibodies Sales Forecast by Region (2027-2032) & (Unit)
Table 84. APAC Anti-IL-23 p19 Monoclonal Antibodies Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 85. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Forecast by Country (2027-2032) & (Unit)
Table 86. Europe Anti-IL-23 p19 Monoclonal Antibodies Revenue Forecast by Country (2027-2032) & ($ millions)
Table 87. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Forecast by Country (2027-2032) & (Unit)
Table 88. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Revenue Forecast by Country (2027-2032) & ($ millions)
Table 89. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Forecast by Indication (2027-2032) & (Unit)
Table 90. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Forecast by Indication (2027-2032) & ($ millions)
Table 91. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Forecast by Application (2027-2032) & (Unit)
Table 92. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Forecast by Application (2027-2032) & ($ millions)
Table 93. AbbVie Inc. Basic Information, Anti-IL-23 p19 Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 94. AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
Table 95. AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Sales (Unit), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. AbbVie Inc. Main Business
Table 97. AbbVie Inc. Latest Developments
Table 98. Johnson & Johnson Basic Information, Anti-IL-23 p19 Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 99. Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
Table 100. Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Sales (Unit), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Johnson & Johnson Main Business
Table 102. Johnson & Johnson Latest Developments
Table 103. Eli Lilly and Company Basic Information, Anti-IL-23 p19 Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 104. Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
Table 105. Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Sales (Unit), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Eli Lilly and Company Main Business
Table 107. Eli Lilly and Company Latest Developments
Table 108. Sun Pharmaceutical Industries Limited Basic Information, Anti-IL-23 p19 Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 109. Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
Table 110. Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Sales (Unit), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Sun Pharmaceutical Industries Limited Main Business
Table 112. Sun Pharmaceutical Industries Limited Latest Developments
Table 113. Innovent Biologics, Inc. Basic Information, Anti-IL-23 p19 Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 114. Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
Table 115. Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Sales (Unit), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Innovent Biologics, Inc. Main Business
Table 117. Innovent Biologics, Inc. Latest Developments
Table 118. Hansoh Pharmaceutical Group Company Limited Basic Information, Anti-IL-23 p19 Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 119. Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
Table 120. Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Sales (Unit), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Hansoh Pharmaceutical Group Company Limited Main Business
Table 122. Hansoh Pharmaceutical Group Company Limited Latest Developments
Table 123. SUN Pharmaceuticals Industries Europe B.V. Basic Information, Anti-IL-23 p19 Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 124. SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
Table 125. SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Sales (Unit), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. SUN Pharmaceuticals Industries Europe B.V. Main Business
Table 127. SUN Pharmaceuticals Industries Europe B.V. Latest Developments
Table 128. Industrias Farmac?uticas Almirall, S.A. Basic Information, Anti-IL-23 p19 Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 129. Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
Table 130. Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Sales (Unit), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Industrias Farmac?uticas Almirall, S.A. Main Business
Table 132. Industrias Farmac?uticas Almirall, S.A. Latest Developments
Table 1. Anti-IL-23 p19 Monoclonal Antibodies Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Anti-IL-23 p19 Monoclonal Antibodies Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Plaque Psoriasis
Table 4. Major Players of Psoriatic Arthritis
Table 5. Major Players of Crohn's Disease
Table 6. Major Players of Ulcerative Colitis
Table 7. Major Players of Others
Table 8. Global Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication (2021-2026) & (Unit)
Table 9. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Indication (2021-2026)
Table 10. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Indication (2021-2026) & ($ million)
Table 11. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Indication (2021-2026)
Table 12. Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Indication (2021-2026) & (US$/Unit)
Table 13. Major Players of Humanized IgG Monoclonal Antibodies
Table 14. Major Players of Fully Human IgG Monoclonal Antibodies
Table 15. Major Players of Fc-engineered or Long-acting Antibodies
Table 16. Major Players of Others
Table 17. Global Anti-IL-23 p19 Monoclonal Antibodies Sales by Molecule Type (2021-2026) & (Unit)
Table 18. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Molecule Type (2021-2026)
Table 19. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Molecule Type (2021-2026) & ($ million)
Table 20. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Molecule Type (2021-2026)
Table 21. Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Molecule Type (2021-2026) & (US$/Unit)
Table 22. Major Players of Subcutaneous Injection
Table 23. Major Players of Intravenous Induction plus Subcutaneous Maintenance
Table 24. Major Players of Intravenous Injection
Table 25. Major Players of Others
Table 26. Global Anti-IL-23 p19 Monoclonal Antibodies Sales by Route of Administration (2021-2026) & (Unit)
Table 27. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Route of Administration (2021-2026)
Table 28. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Route of Administration (2021-2026) & ($ million)
Table 29. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Route of Administration (2021-2026)
Table 30. Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Route of Administration (2021-2026) & (US$/Unit)
Table 31. Global Anti-IL-23 p19 Monoclonal Antibodies Sale by Application (2021-2026) & (Unit)
Table 32. Global Anti-IL-23 p19 Monoclonal Antibodies Sale Market Share by Application (2021-2026)
Table 33. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Application (2021-2026) & ($ million)
Table 34. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Application (2021-2026)
Table 35. Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Application (2021-2026) & (US$/Unit)
Table 36. Global Anti-IL-23 p19 Monoclonal Antibodies Sales by Company (2021-2026) & (Unit)
Table 37. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Company (2021-2026)
Table 38. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Company (2021-2026) & ($ millions)
Table 39. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Company (2021-2026)
Table 40. Global Anti-IL-23 p19 Monoclonal Antibodies Sale Price by Company (2021-2026) & (US$/Unit)
Table 41. Key Manufacturers Anti-IL-23 p19 Monoclonal Antibodies Producing Area Distribution and Sales Area
Table 42. Players Anti-IL-23 p19 Monoclonal Antibodies Products Offered
Table 43. Anti-IL-23 p19 Monoclonal Antibodies Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 44. New Products and Potential Entrants
Table 45. Market M&A Activity & Strategy
Table 46. Global Anti-IL-23 p19 Monoclonal Antibodies Sales by Geographic Region (2021-2026) & (Unit)
Table 47. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share Geographic Region (2021-2026)
Table 48. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Geographic Region (2021-2026) & ($ millions)
Table 49. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Geographic Region (2021-2026)
Table 50. Global Anti-IL-23 p19 Monoclonal Antibodies Sales by Country/Region (2021-2026) & (Unit)
Table 51. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Country/Region (2021-2026)
Table 52. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue by Country/Region (2021-2026) & ($ millions)
Table 53. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Country/Region (2021-2026)
Table 54. Americas Anti-IL-23 p19 Monoclonal Antibodies Sales by Country (2021-2026) & (Unit)
Table 55. Americas Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Country (2021-2026)
Table 56. Americas Anti-IL-23 p19 Monoclonal Antibodies Revenue by Country (2021-2026) & ($ millions)
Table 57. Americas Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication (2021-2026) & (Unit)
Table 58. Americas Anti-IL-23 p19 Monoclonal Antibodies Sales by Application (2021-2026) & (Unit)
Table 59. APAC Anti-IL-23 p19 Monoclonal Antibodies Sales by Region (2021-2026) & (Unit)
Table 60. APAC Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Region (2021-2026)
Table 61. APAC Anti-IL-23 p19 Monoclonal Antibodies Revenue by Region (2021-2026) & ($ millions)
Table 62. APAC Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication (2021-2026) & (Unit)
Table 63. APAC Anti-IL-23 p19 Monoclonal Antibodies Sales by Application (2021-2026) & (Unit)
Table 64. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales by Country (2021-2026) & (Unit)
Table 65. Europe Anti-IL-23 p19 Monoclonal Antibodies Revenue by Country (2021-2026) & ($ millions)
Table 66. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication (2021-2026) & (Unit)
Table 67. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales by Application (2021-2026) & (Unit)
Table 68. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales by Country (2021-2026) & (Unit)
Table 69. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Country (2021-2026)
Table 70. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales by Indication (2021-2026) & (Unit)
Table 71. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales by Application (2021-2026) & (Unit)
Table 72. Key Market Drivers & Growth Opportunities of Anti-IL-23 p19 Monoclonal Antibodies
Table 73. Key Market Challenges & Risks of Anti-IL-23 p19 Monoclonal Antibodies
Table 74. Key Industry Trends of Anti-IL-23 p19 Monoclonal Antibodies
Table 75. Anti-IL-23 p19 Monoclonal Antibodies Raw Material
Table 76. Key Suppliers of Raw Materials
Table 77. Anti-IL-23 p19 Monoclonal Antibodies Distributors List
Table 78. Anti-IL-23 p19 Monoclonal Antibodies Customer List
Table 79. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Forecast by Region (2027-2032) & (Unit)
Table 80. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Americas Anti-IL-23 p19 Monoclonal Antibodies Sales Forecast by Country (2027-2032) & (Unit)
Table 82. Americas Anti-IL-23 p19 Monoclonal Antibodies Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. APAC Anti-IL-23 p19 Monoclonal Antibodies Sales Forecast by Region (2027-2032) & (Unit)
Table 84. APAC Anti-IL-23 p19 Monoclonal Antibodies Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 85. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Forecast by Country (2027-2032) & (Unit)
Table 86. Europe Anti-IL-23 p19 Monoclonal Antibodies Revenue Forecast by Country (2027-2032) & ($ millions)
Table 87. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Forecast by Country (2027-2032) & (Unit)
Table 88. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Revenue Forecast by Country (2027-2032) & ($ millions)
Table 89. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Forecast by Indication (2027-2032) & (Unit)
Table 90. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Forecast by Indication (2027-2032) & ($ millions)
Table 91. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Forecast by Application (2027-2032) & (Unit)
Table 92. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Forecast by Application (2027-2032) & ($ millions)
Table 93. AbbVie Inc. Basic Information, Anti-IL-23 p19 Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 94. AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
Table 95. AbbVie Inc. Anti-IL-23 p19 Monoclonal Antibodies Sales (Unit), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. AbbVie Inc. Main Business
Table 97. AbbVie Inc. Latest Developments
Table 98. Johnson & Johnson Basic Information, Anti-IL-23 p19 Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 99. Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
Table 100. Johnson & Johnson Anti-IL-23 p19 Monoclonal Antibodies Sales (Unit), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Johnson & Johnson Main Business
Table 102. Johnson & Johnson Latest Developments
Table 103. Eli Lilly and Company Basic Information, Anti-IL-23 p19 Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 104. Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
Table 105. Eli Lilly and Company Anti-IL-23 p19 Monoclonal Antibodies Sales (Unit), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Eli Lilly and Company Main Business
Table 107. Eli Lilly and Company Latest Developments
Table 108. Sun Pharmaceutical Industries Limited Basic Information, Anti-IL-23 p19 Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 109. Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
Table 110. Sun Pharmaceutical Industries Limited Anti-IL-23 p19 Monoclonal Antibodies Sales (Unit), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Sun Pharmaceutical Industries Limited Main Business
Table 112. Sun Pharmaceutical Industries Limited Latest Developments
Table 113. Innovent Biologics, Inc. Basic Information, Anti-IL-23 p19 Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 114. Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
Table 115. Innovent Biologics, Inc. Anti-IL-23 p19 Monoclonal Antibodies Sales (Unit), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Innovent Biologics, Inc. Main Business
Table 117. Innovent Biologics, Inc. Latest Developments
Table 118. Hansoh Pharmaceutical Group Company Limited Basic Information, Anti-IL-23 p19 Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 119. Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
Table 120. Hansoh Pharmaceutical Group Company Limited Anti-IL-23 p19 Monoclonal Antibodies Sales (Unit), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Hansoh Pharmaceutical Group Company Limited Main Business
Table 122. Hansoh Pharmaceutical Group Company Limited Latest Developments
Table 123. SUN Pharmaceuticals Industries Europe B.V. Basic Information, Anti-IL-23 p19 Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 124. SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
Table 125. SUN Pharmaceuticals Industries Europe B.V. Anti-IL-23 p19 Monoclonal Antibodies Sales (Unit), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. SUN Pharmaceuticals Industries Europe B.V. Main Business
Table 127. SUN Pharmaceuticals Industries Europe B.V. Latest Developments
Table 128. Industrias Farmac?uticas Almirall, S.A. Basic Information, Anti-IL-23 p19 Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 129. Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Product Portfolios and Specifications
Table 130. Industrias Farmac?uticas Almirall, S.A. Anti-IL-23 p19 Monoclonal Antibodies Sales (Unit), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Industrias Farmac?uticas Almirall, S.A. Main Business
Table 132. Industrias Farmac?uticas Almirall, S.A. Latest Developments
LIST OF FIGURES
Figure 1. Picture of Anti-IL-23 p19 Monoclonal Antibodies
Figure 2. Anti-IL-23 p19 Monoclonal Antibodies Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Growth Rate 2021-2032 (Unit)
Figure 7. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Anti-IL-23 p19 Monoclonal Antibodies Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Country/Region (2025)
Figure 10. Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Plaque Psoriasis
Figure 12. Product Picture of Psoriatic Arthritis
Figure 13. Product Picture of Crohn's Disease
Figure 14. Product Picture of Ulcerative Colitis
Figure 15. Product Picture of Others
Figure 16. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Indication in 2026
Figure 17. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Indication (2021-2026)
Figure 18. Product Picture of Humanized IgG Monoclonal Antibodies
Figure 19. Product Picture of Fully Human IgG Monoclonal Antibodies
Figure 20. Product Picture of Fc-engineered or Long-acting Antibodies
Figure 21. Product Picture of Others
Figure 22. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Molecule Type in 2026
Figure 23. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Molecule Type (2021-2026)
Figure 24. Product Picture of Subcutaneous Injection
Figure 25. Product Picture of Intravenous Induction plus Subcutaneous Maintenance
Figure 26. Product Picture of Intravenous Injection
Figure 27. Product Picture of Others
Figure 28. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Route of Administration in 2026
Figure 29. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Route of Administration (2021-2026)
Figure 30. Anti-IL-23 p19 Monoclonal Antibodies Consumed in Hospitals
Figure 31. Global Anti-IL-23 p19 Monoclonal Antibodies Market: Hospitals (2021-2026) & (Unit)
Figure 32. Anti-IL-23 p19 Monoclonal Antibodies Consumed in Specialist Clinics
Figure 33. Global Anti-IL-23 p19 Monoclonal Antibodies Market: Specialist Clinics (2021-2026) & (Unit)
Figure 34. Anti-IL-23 p19 Monoclonal Antibodies Consumed in Infusion Centers
Figure 35. Global Anti-IL-23 p19 Monoclonal Antibodies Market: Infusion Centers (2021-2026) & (Unit)
Figure 36. Anti-IL-23 p19 Monoclonal Antibodies Consumed in Specialty Pharmacies
Figure 37. Global Anti-IL-23 p19 Monoclonal Antibodies Market: Specialty Pharmacies (2021-2026) & (Unit)
Figure 38. Anti-IL-23 p19 Monoclonal Antibodies Consumed in Retail and DTP Pharmacies
Figure 39. Global Anti-IL-23 p19 Monoclonal Antibodies Market: Retail and DTP Pharmacies (2021-2026) & (Unit)
Figure 40. Anti-IL-23 p19 Monoclonal Antibodies Consumed in Others
Figure 41. Global Anti-IL-23 p19 Monoclonal Antibodies Market: Others (2021-2026) & (Unit)
Figure 42. Global Anti-IL-23 p19 Monoclonal Antibodies Sale Market Share by Application (2025)
Figure 43. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Application in 2025
Figure 44. Anti-IL-23 p19 Monoclonal Antibodies Sales by Company in 2025 (Unit)
Figure 45. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Company in 2025
Figure 46. Anti-IL-23 p19 Monoclonal Antibodies Revenue by Company in 2025 ($ millions)
Figure 47. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Company in 2025
Figure 48. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Geographic Region (2021-2026)
Figure 49. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Geographic Region in 2025
Figure 50. Americas Anti-IL-23 p19 Monoclonal Antibodies Sales 2021-2026 (Unit)
Figure 51. Americas Anti-IL-23 p19 Monoclonal Antibodies Revenue 2021-2026 ($ millions)
Figure 52. APAC Anti-IL-23 p19 Monoclonal Antibodies Sales 2021-2026 (Unit)
Figure 53. APAC Anti-IL-23 p19 Monoclonal Antibodies Revenue 2021-2026 ($ millions)
Figure 54. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales 2021-2026 (Unit)
Figure 55. Europe Anti-IL-23 p19 Monoclonal Antibodies Revenue 2021-2026 ($ millions)
Figure 56. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales 2021-2026 (Unit)
Figure 57. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Revenue 2021-2026 ($ millions)
Figure 58. Americas Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Country in 2025
Figure 59. Americas Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Country (2021-2026)
Figure 60. Americas Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Indication (2021-2026)
Figure 61. Americas Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Application (2021-2026)
Figure 62. United States Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 63. Canada Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 64. Mexico Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 65. Brazil Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 66. APAC Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Region in 2025
Figure 67. APAC Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Region (2021-2026)
Figure 68. APAC Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Indication (2021-2026)
Figure 69. APAC Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Application (2021-2026)
Figure 70. China Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 71. Japan Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 72. South Korea Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 73. Southeast Asia Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 74. India Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 75. Australia Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 76. China Taiwan Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 77. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Country in 2025
Figure 78. Europe Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Country (2021-2026)
Figure 79. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Indication (2021-2026)
Figure 80. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Application (2021-2026)
Figure 81. Germany Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 82. France Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 83. UK Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 84. Italy Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 85. Russia Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 86. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Country (2021-2026)
Figure 87. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Indication (2021-2026)
Figure 88. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Application (2021-2026)
Figure 89. Egypt Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 90. South Africa Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 91. Israel Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 92. Turkey Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 93. GCC Countries Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 94. Manufacturing Cost Structure Analysis of Anti-IL-23 p19 Monoclonal Antibodies in 2026
Figure 95. Manufacturing Process Analysis of Anti-IL-23 p19 Monoclonal Antibodies
Figure 96. Industry Chain Structure of Anti-IL-23 p19 Monoclonal Antibodies
Figure 97. Channels of Distribution
Figure 98. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Forecast by Region (2027-2032)
Figure 99. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share Forecast by Region (2027-2032)
Figure 100. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share Forecast by Indication (2027-2032)
Figure 101. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share Forecast by Indication (2027-2032)
Figure 102. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share Forecast by Application (2027-2032)
Figure 103. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Anti-IL-23 p19 Monoclonal Antibodies
Figure 2. Anti-IL-23 p19 Monoclonal Antibodies Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Growth Rate 2021-2032 (Unit)
Figure 7. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Anti-IL-23 p19 Monoclonal Antibodies Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Country/Region (2025)
Figure 10. Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Plaque Psoriasis
Figure 12. Product Picture of Psoriatic Arthritis
Figure 13. Product Picture of Crohn's Disease
Figure 14. Product Picture of Ulcerative Colitis
Figure 15. Product Picture of Others
Figure 16. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Indication in 2026
Figure 17. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Indication (2021-2026)
Figure 18. Product Picture of Humanized IgG Monoclonal Antibodies
Figure 19. Product Picture of Fully Human IgG Monoclonal Antibodies
Figure 20. Product Picture of Fc-engineered or Long-acting Antibodies
Figure 21. Product Picture of Others
Figure 22. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Molecule Type in 2026
Figure 23. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Molecule Type (2021-2026)
Figure 24. Product Picture of Subcutaneous Injection
Figure 25. Product Picture of Intravenous Induction plus Subcutaneous Maintenance
Figure 26. Product Picture of Intravenous Injection
Figure 27. Product Picture of Others
Figure 28. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Route of Administration in 2026
Figure 29. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Route of Administration (2021-2026)
Figure 30. Anti-IL-23 p19 Monoclonal Antibodies Consumed in Hospitals
Figure 31. Global Anti-IL-23 p19 Monoclonal Antibodies Market: Hospitals (2021-2026) & (Unit)
Figure 32. Anti-IL-23 p19 Monoclonal Antibodies Consumed in Specialist Clinics
Figure 33. Global Anti-IL-23 p19 Monoclonal Antibodies Market: Specialist Clinics (2021-2026) & (Unit)
Figure 34. Anti-IL-23 p19 Monoclonal Antibodies Consumed in Infusion Centers
Figure 35. Global Anti-IL-23 p19 Monoclonal Antibodies Market: Infusion Centers (2021-2026) & (Unit)
Figure 36. Anti-IL-23 p19 Monoclonal Antibodies Consumed in Specialty Pharmacies
Figure 37. Global Anti-IL-23 p19 Monoclonal Antibodies Market: Specialty Pharmacies (2021-2026) & (Unit)
Figure 38. Anti-IL-23 p19 Monoclonal Antibodies Consumed in Retail and DTP Pharmacies
Figure 39. Global Anti-IL-23 p19 Monoclonal Antibodies Market: Retail and DTP Pharmacies (2021-2026) & (Unit)
Figure 40. Anti-IL-23 p19 Monoclonal Antibodies Consumed in Others
Figure 41. Global Anti-IL-23 p19 Monoclonal Antibodies Market: Others (2021-2026) & (Unit)
Figure 42. Global Anti-IL-23 p19 Monoclonal Antibodies Sale Market Share by Application (2025)
Figure 43. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Application in 2025
Figure 44. Anti-IL-23 p19 Monoclonal Antibodies Sales by Company in 2025 (Unit)
Figure 45. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Company in 2025
Figure 46. Anti-IL-23 p19 Monoclonal Antibodies Revenue by Company in 2025 ($ millions)
Figure 47. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Company in 2025
Figure 48. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Geographic Region (2021-2026)
Figure 49. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Geographic Region in 2025
Figure 50. Americas Anti-IL-23 p19 Monoclonal Antibodies Sales 2021-2026 (Unit)
Figure 51. Americas Anti-IL-23 p19 Monoclonal Antibodies Revenue 2021-2026 ($ millions)
Figure 52. APAC Anti-IL-23 p19 Monoclonal Antibodies Sales 2021-2026 (Unit)
Figure 53. APAC Anti-IL-23 p19 Monoclonal Antibodies Revenue 2021-2026 ($ millions)
Figure 54. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales 2021-2026 (Unit)
Figure 55. Europe Anti-IL-23 p19 Monoclonal Antibodies Revenue 2021-2026 ($ millions)
Figure 56. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales 2021-2026 (Unit)
Figure 57. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Revenue 2021-2026 ($ millions)
Figure 58. Americas Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Country in 2025
Figure 59. Americas Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Country (2021-2026)
Figure 60. Americas Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Indication (2021-2026)
Figure 61. Americas Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Application (2021-2026)
Figure 62. United States Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 63. Canada Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 64. Mexico Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 65. Brazil Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 66. APAC Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Region in 2025
Figure 67. APAC Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Region (2021-2026)
Figure 68. APAC Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Indication (2021-2026)
Figure 69. APAC Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Application (2021-2026)
Figure 70. China Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 71. Japan Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 72. South Korea Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 73. Southeast Asia Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 74. India Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 75. Australia Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 76. China Taiwan Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 77. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Country in 2025
Figure 78. Europe Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share by Country (2021-2026)
Figure 79. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Indication (2021-2026)
Figure 80. Europe Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Application (2021-2026)
Figure 81. Germany Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 82. France Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 83. UK Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 84. Italy Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 85. Russia Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 86. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Country (2021-2026)
Figure 87. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Indication (2021-2026)
Figure 88. Middle East & Africa Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share by Application (2021-2026)
Figure 89. Egypt Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 90. South Africa Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 91. Israel Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 92. Turkey Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 93. GCC Countries Anti-IL-23 p19 Monoclonal Antibodies Revenue Growth 2021-2026 ($ millions)
Figure 94. Manufacturing Cost Structure Analysis of Anti-IL-23 p19 Monoclonal Antibodies in 2026
Figure 95. Manufacturing Process Analysis of Anti-IL-23 p19 Monoclonal Antibodies
Figure 96. Industry Chain Structure of Anti-IL-23 p19 Monoclonal Antibodies
Figure 97. Channels of Distribution
Figure 98. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Forecast by Region (2027-2032)
Figure 99. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share Forecast by Region (2027-2032)
Figure 100. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share Forecast by Indication (2027-2032)
Figure 101. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share Forecast by Indication (2027-2032)
Figure 102. Global Anti-IL-23 p19 Monoclonal Antibodies Sales Market Share Forecast by Application (2027-2032)
Figure 103. Global Anti-IL-23 p19 Monoclonal Antibodies Revenue Market Share Forecast by Application (2027-2032)
